Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer

Gu, Mei-Ling; Zhai, Zhenhua; Huang, Li; Zheng, Wenjiao; Zhou, Yi‐Chao; Zhu, Ruiqi; Shen, Feifei; Yuan, Caijun

doi:10.1007/s12282-015-0635-6

Cited by 65 publications

(61 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, it was observed that increased mean platelet volume was associated with larger tumors, higher stage, distant metastases and a poorer prognosis in patients with breast cancer (23). By contrast, Yao et al (18) reported that there was no significant difference in survival between higher and lower mean platelet volumes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma

et al. 2016

View full text Add to dashboard Cite

Abstract.A growing body of evidence suggests that oncogenesis is associated with systemic inflammation. The present study investigated white blood cell and platelet indices, whose values change during the inflammatory response, in women with invasive ductal breast carcinoma. Preoperatively obtained white blood cell and platelet counts from 53 patients with early breast cancer, who developed systemic metastases over a mean follow-up period of 65 months, were analyzed and compared with those of a matching control group formed of 37 patients with the same characteristics, who remained recurrence-free during the same time period. Patients who developed distant metastasis had a significantly higher mean platelet volume and lower neutrophil count than patients who did not present with distant metastasis. Furthermore, time to distant metastasis development was longer in patients with a lower mean platelet volume, whilst patients with a lower neutrophil count had a shorter systemic disease-free time interval. However, receiver operating characteristic curve analysis demonstrated that these parameters provided moderate accuracy in predicting which patients may develop distant metastasis. No differences were detected between patient groups regarding additional parameters. Patients who developed systemic disease during a mean follow-up period of 65 months were observed to have an increased mean platelet volume and decreased neutrophil count preoperatively. These results indicate that such parameters may be of prognostic value in patients with breast cancer. Studies with a larger number of patients are required to further investigate this hypothesis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Gu et al (23) reported that mean platelet volume is higher in patients with breast cancer than in patients with benign breast tumors. Additionally, it was observed that increased mean platelet volume was associated with larger tumors, higher stage, distant metastases and a poorer prognosis in patients with breast cancer (23).…”

Section: Discussionmentioning

confidence: 99%

White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For instance, previous studies have reported that the MPV was higher in patients with gastric cancer than in control patients and that the MPV/PC (platelet count) ratio was meaningfully increased in patients with hepatocellular carcinoma [29, 30]. In addition, published research has reported a significant correlation between high MPV and advanced cancer, such as gastric cancer [16], hepatocellular carcinoma [30], endometrial cancer [15], breast cancer [31], and colon cancer [32]. It has been proposed that inflammatory cytokines, such as interleukin-6, produced by tumour cells may stimulate the differentiation and proliferation of megakaryocytes to produce abundant giant platelets.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer

Gao

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The aim of the present study was to investigate the prognostic value of the combination of preoperative platelet count (PLT) and mean platelet volume (MPV) in patients with primary operable non-small cell lung cancer (NSCLC). We retrospectively analysed data from 546 patients with NSCLC who underwent complete resection at our institution from 2006 to 2010. Patients’ clinical characteristics and laboratory test data at initial diagnosis were collected. Both preoperative PLT and MPV (COP-MPV) were calculated on the basis of the data obtained using the recommended cut-off values of 300 × 109 L−1 and 11.0 fL, respectively. Patients with both an elevated PLT (≥300× 109 L−1) and a decreased MPV (<11.0 fL) were assigned a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively. Multivariate analysis of the 9 clinical laboratory variables selected by univariate analysis revealed that preoperative COP-MPV was a significantly independent prognostic factor for overall survival (OS) (hazard ratio, 1.775; 95% confidence interval, 1.500–2.101; P< 0.001) and disease-free survival (DFS) (hazard ratio, 1.719; 95% confidence interval, 1.454–2.033; P< 0.001). In subgroup analyses for tumour pathological stage (I/II/IIIA) patients, we found that the level of COP-MPV was significantly associated with OS and DFS in each subgroup (P< 0.001, P< 0.001, P<0.001 for OS and P<0.001, P< 0.001, P=0.001 for DFS, respectively). In conclusion, the preoperative COP-MPV is a promising predictor of postoperative survival in patients with NSCLC and could classify these patients into three independent groups before surgery.

show abstract

“…Despite the availability of clinical and experimental data in support of an active involvement of the haemostatic system in cancer dissemination and progression, our current understanding of the role of platelets in BC progression is still modest . Increased platelet activation has been occasionally reported in BC patients, but clinical data are limited and the association with clinical–pathological features in BC is controversial, mostly depending on the biomarker used in the analysis . Indeed, pre‐activation due to methodological pitfalls is one of the major risks when analyzing platelet‐derived biomarkers, a possibility that together with an inaccurate choice of controls (as in vivo platelet activation can occur in obese women, or with T2D) might have underpowered many of the studies.…”

Section: Discussionmentioning

confidence: 99%

Oxidant stress as a major determinant of platelet activation in invasive breast cancer

et al. 2016

View full text Add to dashboard Cite

The hypothesis that increased oxidative stress in breast cancer (BC) patients could induce enhanced lipid peroxidation, which, in turn, would contribute to platelet activation and poor clinical outcome is attractive. To address this issue, we investigated pre-surgical urinary 8-iso-prostaglandin (PG)F (marker of in vivo oxidative stress) and 11-dehydro-thromboxane (TX)B (marker of in vivo platelet activation) levels in patients with primary BC (n = 115) compared with control women paired for comorbidities and their association with patients' metabolic profile and clinical prognostic factors. The results obtained showed that presurgical urinary excretion of both biomarkers was enhanced in BC patients compared to controls and was associated with patients' estrogen receptor (ER) expression, but not HER2 status or Ki67 proliferation index. Accordingly, both urinary biomarkers were increased in patients with luminal-like BC molecular subtypes compared with triple negative or HER2-enriched tumors. ER status was an independent predictor of 8-iso-PGF urinary levels, which, in turn, significantly predicted 11-dehydro-TXB urinary levels together with disease stage and ER status. The prognostic value of 11-dehydro-TXB was then evaluated showing a significant correlation with BC pathological response to neoadjuvant treatment. Furthermore, among relapsing patients, those with elevated urinary biomarker levels were more likely to develop distant metastasis rather than local recurrence. In conclusion, we may speculate that enhanced oxidative stress due to estrogen-related mechanisms might cause a condition of persistent platelet activation capable of sustaining BC growth and progression through the release of bioactive stored molecules, ultimately contributing to tumor invasiveness. Further studies specifically addressing this hypothesis are presently needed.

show abstract

Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer

Abstract: High pre-treatment MPV level in IBC patients was a potential predictive factor and significant independent prognostic factor.

Cited by 65 publications

References 31 publications

White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma

White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma

Prognostic value of combination of preoperative platelet count and mean platelet volume in patients with resectable non-small cell lung cancer

Oxidant stress as a major determinant of platelet activation in invasive breast cancer

Contact Info

Product

Resources

About